Repligen RGEN 深 沪
已收盘 08-07 16:00:00 美东时间
163.90
+4.460
+2.80%
华盛通- 最 高164.97
- 今 开159.44
- 成交量 95.05万股
- 最 低 159.44
- 昨 收 159.44
- 总市值 92.50亿
- 52周最高 175.77
- 市盈率 静 189.61
- 换手率 1.68%
- 52周最低 100.99
- 委 比 82.79%
- 总股本 5643.56万
- 历史最高 327.32
- 量 比 0.85
- 振 幅 3.47%
- 历史最低 2.90
- 每 手 1
- 风险率 18.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioLife Details Strategic Repligen Merger Communication to Staff
BioLife Solutions ( ($BLFS) ) has provided an update. On July 21, 2026, BioLife...
08-04 06:21
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
财报速睇 | Repligen 2026财年Q2营收2.04亿美元，同比增长11.9%；归母净利润0.05亿美元，同比下滑66.3%
华盛资讯7月30日讯，Repligen公布2026财年Q2业绩，公司Q2营收2.04亿美元，同比增长11.9%，归母净利润0.05亿美元，同比下滑66.3%。
07-30 04:37
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175
JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $165 to $175.
07-30 02:36
Repligen soars 16% after blockbuster earnings, FY25 guidance upgrade
Repligen (RGEN) shares rose as much as 16% during Tuesday’s trading following blockbuster second-quarter results and an upward revision to its full-year guidance. RGEN shares advanced 15.91% to $151.9...
07-29 02:49
财报速睇 | Repligen 2026财年Q2营收2.04亿美元，同比增长12.1%；归母净利润0.05亿美元，同比下滑66.7%
华盛资讯7月28日讯，Repligen公布2026财年Q2业绩，公司Q2营收2.04亿美元，同比增长12.1%，归母净利润0.05亿美元，同比下滑66.7%。
07-28 19:32
Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.45 by 20 percent. This is a 45.95 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $204.128 million which bea...
07-28 19:02
Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M to $813.000M-$835.000M vs $822.537M Est
Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 analyst estimate. Raises FY2026 sales outlook from $803.000 million-$833.000 million to $813.000 million-$835.000 million vs $822.537 million estimate.
07-28 19:01
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion. Repligen Expands Into Cell Therapy The acquisition aims to capitalize on the rapidly expanding...
07-22 21:41
BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5B
BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, which equates to a total value of $31.00 per share. This represents an implied premium of 24% to 90-day volume-weighted average price (VWAP) for the period ended July 21, 2026. Repligen Corporation...
07-22 18:03
